微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 89.02% | 3.68% | 1.61% | 9/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 87.61% | 3.76% | 1.27% | 11/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 86.51% | 3.07% | -0.3% | 12/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 86.77% | 2.78% | 1.06% | 10/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 85.86% | 2.74% | 1.68% | 9/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 84.44% | -0.15% | 0.6% | 14/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 83.94% | -1.53% | -0.58% | 13/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 84.42% | 1% | 1.02% | 13/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 83.57% | 2.13% | -1.17% | 13/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 84.57% | 5.46% | -0.79% | 12/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 85.24% | 7.21% | 1.97% | 13/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 83.59% | 6.26% | 2.15% | 14/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 81.84% | 3.99% | 2.06% | 21/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 80.18% | -6.78% | 0.85% | 21/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 79.51% | -9.56% | 1.07% | 22/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 78.67% | -13.45% | -0.04% | 26/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 78.69% | 2% | -8.51% | 25/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 86.02% | 10.77% | -2.16% | 15/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 87.91% | 14.84% | -3.28% | 10/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 90.89% | 2% | 17.05% | 8/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2020-12-31 | 77.65% | -6.86% | 1.44% | 26/157 | -148.64% | 艾力斯 | 98.7% | 行业排名> |
| 2020-09-30 | 76.55% | 2% | -8.18% | 22/157 | 56.43% | 艾力斯 | 99.4% | 行业排名> |
| 2019-12-31 | 83.38% | -2.51% | -2.51% | 13/157 | -1242.15% | 首药控股 | 99.94% | 行业排名> |
| 2018-12-31 | 85.52% | 2% | 2% | 15/157 | -211.97% | 泽璟制药 | 99.96% | 行业排名> |